Furthermore, Gramatzki et al. mentioned that prognostic factors, including isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, may affect bevacizumab treatment in patients with recurrent cancer. This evidence concerns the gene IDH3A and cancer.